1. 477OTepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study. (24th November 2019) Authors: Park, K; Zhou, J; Kim, D-W; Ahmad, A R; Soo, R A; Bruns, R; Straub, J; Johne, A; Scheele, J; Yang, J C-H; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 515PTepotinib + gefitinib (TEP+GEF) in MET+/epidermal growth factor receptor (EGFR)-mutant non-small lung cancer (NSCLC): Phase II data. (25th November 2018) Authors: Wu, Y-L; Zhou, J; Lu, S; Zhang, Y; Zhao, J; Pan, H; Chen, Y-M; Chian, C-F; Bruns, R; Johne, A; Scheele, J; Cheng, Y Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 536TiPINSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study. (24th November 2019) Authors: Yang, J C-H; Ellers-Lenz, B; Straub, J; Johne, A; Wu, Y-L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗